EMOL Health, a data aggregation company for community oncology practices, Ajeet Gajra, MD, and
G1 Therapeutics presented a poster at the 2023 ASCO Quality Care Symposium in Boston.
Myelosuppression and healthcare utilization among patients with chemotherapy-treated
extensive-stage small cell lung cancer (ES-SCLC) with and without trilaciclib from
community oncology practices. (Abstract #527)
Using EMRs from participating community oncology practices, EMOL Health’s Curation Team read
through EMRs to collect data on ES-SCLC patients receiving trilaciclib and chemotherapy to a
comparison cohort not receiving trilaciclib. Results from this study suggest that trilaciclib reduces
myelosuppression and cytopenia-related healthcare utilization among patients with ES-SCLC
in the real world.
For Absract link, click here.